kabutan

NIPPON CHEMIPHAR CO., LTD.(4539) Summary

4539
TSE Standard
NIPPON CHEMIPHAR CO., LTD.
1,527
JPY
+4
(+0.26%)
Dec 5, 11:30 am JST
9.84
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
36.7
PBR
0.29
Yield
3.27%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
1,525 JPY 9.83 USD
Previous Close Dec 4
1,523 JPY 9.80 USD
High Dec 5, 9:57 am
1,537 JPY 9.91 USD
Low Dec 5, 9:00 am
1,525 JPY 9.82 USD
Volume
900
Trading Value
1.00M JPY 8.90K USD
VWAP
1528.33 JPY 9.89 USD
Minimum Trading Value
152,700 JPY 984 USD
Market Cap
6.51B JPY 0.04B USD
Number of Trades
8
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly Low
1-Year Average
12
1-Year High Sep 11, 2025
83
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 191,100
Nov 21, 2025 0 191,800
Nov 14, 2025 0 194,600
Nov 7, 2025 0 196,000
Oct 31, 2025 0 196,100
Company Profile
NIPPON CHEMIPHAR CO., LTD. is a mid-sized pharmaceutical company. Its main focus is on generic drugs, with uric acid and pain relief medications as its core products. The company is also actively engaged in new drug development.
Sector
Pharmaceuticals
NIPPON CHEMIPHAR CO., LTD. operates in the medical, health, and beauty-related sectors, with pharmaceutical products at its core. In its primary pharmaceutical business, the company manufactures and sells prescription drugs, with a high proportion of generic medicines, while also pursuing new drug development. The company promotes its business in collaboration with domestic and overseas subsidiaries and affiliates. Additionally, it is involved in other ventures such as safety testing services, healthcare business, and real estate leasing. The group comprises six companies, establishing an integrated system from drug development to manufacturing and sales. While maintaining its strength in the prescription drug field, NIPPON CHEMIPHAR CO., LTD. has expanded into related areas, solidifying its position as a comprehensive medical and health-related enterprise.